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(57) ABS TRAC 'I 
A device for the transdermal delivery of a therapeutic agent 
to a biological subject that includes a first electrode com- 
prising a first array of electrically conductive microprojec- 
tions for providing electrical communication through a skin 
portion of the subject to a second electrode comprising a 
second array of electrically conductive microprojections. 
Additionally, a reservoir for holding the therapeutic agent 
surrounding the first electrode and a pulse generator for 
providing an exponential decay pulse between the first and 
second electrodes may be provided. A method includes the 
steps of piercing a stratum corneum layer of skin with two 
arrays of conductive microprojections, encapsulating the 
therapeutic agent into biocompatible charged carriers, sur- 
rounding the conductive microprojections with the thera- 
peutic agent, generating an exponential decay pulse between 
the two arrays of conductive microprojections to create a 
non-uniform electrical field and electrokinetically driving 
the therapeutic agent through the stratum corneum layer of 
skin. 
49 Claims, 4 Drawing Sheets 
22 16 26 
https://ntrs.nasa.gov/search.jsp?R=20080018813 2019-08-30T04:35:33+00:00Z
U.S. Patent Jan. 1,2008 
20.00 
- ca 
a 
0 
= E 10.00 
c, 
5.00 n 
0.00 
Sheet 1 of 4 US 7,315,758 B2 
0.00 10.00 20.00 30.00 40.00 50.00 60.00 
Time [SI FIG. f A  
2.00 
1 .oo 
-1.00 
-2.00 
0.00 10.00 20.00 30.00 40.00 50.00 60.00 
Time [SI 
FIG. IB  
20.00 
15.00 
10.00 
.- m 5.00 - 
Y 
% 0.00 1 1 I * J 
0 
 
-5.00 
-10.00 
0.00 10.00 20.00 30.00 40.00 50.00 60.00 
Time [SI 
U.S. Patent Jan. 1,2008 Sheet 2 of 4 US 7,315,758 B2 
24 - 
23 - 
15\ 
19 23 22 19 26 
- 24 
-- 25 
r 1 4  
- 24 
21 
FIG. 2 
U.S. Patent Jan. 1,2008 Sheet 3 of 4 US 7,315,758 B2 
31 
FIG. 3 A  
28 
U.S. Patent Jan. 1,2008 Sheet 4 of 4 US 7,315,758 B2 
. 
US 7,315,758 B2 
1 2 
TRANSDERMAL DELIVERY OF 
THERAPEUTIC AGENT 
drug by the GI tract is not an issue. Today transdermal 
patches delivery estrogen for hormone replacement therapy, 
nitroglycerine for angina, scopolamine for motion sickness 
This invention was made with government support under and seasickness, fentanyl for pain control, clonidine for 
contract number NAS3-03033 awarded by the National 5 hypertension, and recently ethinylestradiol plus norel- 
Aeronautics and Space Administration (NASA). The gov- gestromin for contraception. 
ernment has certain rights in this invention. Despite these advantages, wearable patches are con- 
strained by the fact that very few drugs can be formulated for 
transdermal delivery. The limitation comes from the highly 
i o  resistive outer-most layer of the skin, the stratum corneum. 
Drugs delivered transdermally must be small enough to 
diffuse through the lipophillic gaps between the skin cells 
and through the skin pores. For this passive delivery, drugs 
must have a large therapeutic window; they must not be 
2. Description of the Related Art 15 toxic at high concentrations yet still potent at low concen- 
Common methods for administering therapeutic mol- trations. Unfortunately, very few drugs meet this require- 
ecules to treat illnesses or injuries to a patient include the use ment. The benefits of wearable patches will not be realized 
of hypodermic needles and oral ingestion. These methods unless methods to enhance drug passage through the stratum 
have limitations. Delivery by oral ingestion or injection by corneum are developed. 
hypodermic syringe can cause drug concentrations in the 20 Iontophoresis is an alternative approach that can be uti- 
body to fluctuate between high and low values, whereas a lized to deliver agents across a tissue by the application of 
sustained or continuous delivery is desirable. Hypodermic an electrical current. In practice, iontophoretic methods 
needle delivery is very unpopular with patients, who are generally provide positioning an electrode having a reservoir 
often reluctant to perform this procedure on themselves. or absorbent pad that contains the agent to be transferred 
Furthermore, safe handling and disposal of the biohazardous 25 onto the tissue through which delivery is to occur. Another 
hypodermic needles is difficult. electrode that typically does not include the agent but 
Oral administration of drugs remains the most common contains, or is coated with, a conductive gel is also placed in 
method of drug delivery because the cells lining the intestine contact with the tissue to complete the electrical circuit. 
tend to be quite permeable and because oral ingestion is Application of a voltage between the two electrodes and 
generally accepted by patients. This approach, however, has 30 across the tissue generates a current that causes the ionized 
a variety of shortcomings including degradation of the agent agent to move towards the electrode of opposite charge, 
within the digestive system, local gastrointestinal irritation, thereby driving the agent through the tissue. Neutral agents 
and noncompliance when patients do not take their prescrip- can also be transported, albeit less effectively than ionized 
tion in a timely manner. Furthermore, some of the drugs agents, via electroosmosis. Iontophoresis also may induce 
resulting from advances in biotechnology are protein based 35 the formation andor enlargement of pores within tissues, 
and cannot be taken orally or they will be digested in the which in turn increases tissue permeability to ionic and polar 
gastrointestinal tract. These difficulties have spurred agents and dives these agents through the enlarged pores. 
research into new ways to deliver therapeutic molecules, When the tissue is skin, the agent penetrates the stratum 
preferably by non-invasive or semi-invasive paths. corneum and then passes through the other layers of the 
Examples include jet injectors, inhalers, and external micro- 40 epidermis into the dermis layer, the second major layer of 
pumps. Unfortunately, there are problems associated with skin. The innermost portion of the dermis is typically 
the few commercially available non-invasive or semi-inva- referred to as the papillary layer and contains a network of 
sive delivery devices. capillaries from the vascular system. This network absorbs 
One non-invasive method of administering drugs being the therapeutic agent and subsequently moves it to the main 
widely studied is the transcutaneous delivery method. The 45 portion of the circulatory system. A problem associated with 
transport of various agents such as metabolites, drugs and drug administration using iontophoresis is that it is appli- 
nutrients across tissues is a function primarily of three cable only to drugs that have an electrical charge. 
factors: tissue permeability, the presence or absence of a While iontophoresis typically utilizes a DC power source 
driving force and the size of the area through which transport to provide a DC current, AC current may also be used for 
occurs. The lack of inherent permeability for many tissues 50 iontophoresis. For example, U.S. Pat. No. 6,512,950 issued 
renders it difficult to move agents across a body surface. The to Li, et al., and hereby fully incorporated by reference, 
permeability of many tissues is low because cell membranes discloses a variety of methods for transporting agents across 
are generally composed of lipid bilayers that are relatively tissue. The disclosed methods utilize an AC signal to main- 
impermeable to ionized and uncharged polar species. For tain a substantially constant electrical state in a region of the 
example, transport of agents across the skin has proven 55 tissue through which transport occurs, thereby allowing the 
difficult in part because the outer layer of skin, termed the agent to be transported across the issue in a controlled and 
stratum corneum, consists of tightly packed cells with inter- predictable manner. 
cellular lipids that severely impede the passage of sub- Another method found to be useful for increasing the 
stances through this barrier. transdermal passage of therapeutic agents has been to per- 
Medicated adhesive patches provide one method for the 60 forate the stratum corneum with microprojections. Perforat- 
transcutaneous administration of drugs. The drug is pre- ing the stratum corneum with an array of microprojections 
loaded and steadily diffuses from the patch through the skin that have very sharp tips, typically having a diameter of 
to blood capillaries in the skin’s deeper layers. Drug patches between about l p  and about 2 pm, significantly reduces the 
are popular for several reasons: 1) they allow sustained drug current required for iontophoresis. U.S. Pat. No. 6,379,324 
delivery, avoiding the concentration peaks and valleys of 65 issued to Gartstein and herein incorporated by reference in 
conventional methods, 2) patients are less likely to forget, 3) its entirety, discloses a microneedle array constructed of 
the drugs are delivered painlessly, and 4) degradation of the silicon and silicon dioxide compounds that may be used to 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to medical devices, and 
more specifically, to an apparatus and method for transder- 
mal delivery of pharmaceuticals. 
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perforate the stratum corneum of the skin to deliver drugs many different forms and of different materials as known to 
into the epidermis through the application of iontophoresis. those having ordinary skill in the art including, for example, 
There is a need to provide caregivers and their patients a conductive mounting rod or a conductive mounting plate 
with procedures and devices that may be used to administer made of a silicon substrate plated with a conductive coating. 
metabolites, drugs and nutrients in a painless manner at 5 The conductive mount may include a nonconductive sub- 
controlled and consistent rates by means that avoid the strate plated with a conductive coating. Examples of mate- 
digestive tract where the drugs or metabolites may be rials for the nonconductive substrate include polyvinylidene 
destroyed through the digestive process. It would be advan- fluoride and polyethylene terephthalate. The conductive 
tageous for these procedures and devices to perform auto- coating plated on the substrate may be, for example, a noble 
matically without patient intervention so that a controlled i o  metal. 
and constant level of therapeutic agent could be delivered to The present invention further includes an electrical power 
the patient. source, which may be selected from many available as 
known to those having ordinary skill in the art. Batteries are 
one suitable power source. Also included in the present 
15 invention is a power inverter for transforming DC current 
The Present invention Provides a Patch forthe transdermal from the one or more batteries or other power source to AC 
delivery of a therapeutic agent to a biological subject that current to the electrodes, 
includes a first electrode comprising a first array of electri- 
cally conductive microprojections for providing electrical therapeutic agents may be microencapsulated within a poly- 
communication through a skin portion of the subject to a 20 mer matrix, such as within microspheres, which may be 
conductive microprojections. The patch further includes a a synthetic copo~ymer or formed from materials 
reservoir for holding the therapeutic agent surrounding the made of collagen or albumin, 
first electrode and a pulse generator for providing an expo- The microspheres preferably have a diameter between nential decay pulse between the first and second electrodes. 25 about 5 microns and about 100 microns or more preferably 
An electronic control module may also be provided. between about 10 microns and about 70 microns. The A second reservoir for holding a second therapeutic agent therapeutic agent may be selectively microencapsulated surrounding the second electrode may be provided. The within a polymer matrix that is negatively charged, posi- therapeutic agent may be the same agent as is contained in tively charged, or has no charge, regardless of whether the the first reservoir or it may be a different agent. The one or 30 therapeutic agent is negatively charged, positively charged, more therapeutic agents are suspended in the reservoirs or has no charge. within a buffer gel. The buffer gel may be an agarose gel or 
may be selected from many iontophoretic gels that are In some embodiments of the present invention, the expo- 
commercially available. Selected buffer gels for the first and nential decay pulse may be superimposed Over a sign wave 
superimposed over a constant current function to offset the different. ne m~cropro~ect~ons are adapted to provide perforation constant current function to a net negative or a net positive 
of the epidermis to a depth of between about 50 pm and current. 
about 150 p. Preferably, the microprojections are adapted The Present invention further Provides m~thods for the 
to transiently perforate the epidermis to a depth greater than 40 trandermal delivery of a therapeutic agent that includes the 
the thickness of a stratum corneum layer of the epidermis but steps of Piercing a stratum corneum layer of skin With two 
less than a depth of sensory nerve ending locations,  hi^ arrays of conductive microprojections, encapsulating the 
provides the desired passages cut through the stratum cor- therapeutic agent into biocompatible charged carriers, sur- 
neum but does not cut deeply enough to contact nerve rounding the conductive microprojections with the thera- 
endings, therefore resulting in painless delivery of the thera- 45 peutic agent, generating an exponential decay Pulse between 
peutic agents, ne diameters of the microprojec~ions may the two arrays of conductive microprojections to create a 
range between about 0.5 pm and about 5 pm and the tips of non-uniform electrical field and electrokinetically driving 
the microprojections may have a diameter of between about the therapeutic agent through the stratum corneum layer of 
1 pm and about 2 p skin. 
In some embodiments of the present invention, the expo- 
known to those having ordinary skill in the art including, nential decay pulse is generated using parameters compris- 
without limitation, tungsten, platinum, silicon, gold and ing a number of pulses, a voltage range, and a time period. 
silver. In some embodiments, the microprojections may be The number of pulses may range between about 100 and 300 
made of etched tungsten wire plated with platinum or gold per minute at a voltage range of between about 3 V and 
or may be made of etched silicon block plated with plati- 55 about 60 V. Preferably, the upper voltage range is between 
num. Microprojections made with silicon are included in about 30 V and about 70 V and the lower voltage range may 
embodiments of the present invention and preferably, are be between about 0.5 V and about 20 V. The time period for 
plated with a metal, including platinum or gold. the exponential decay pulse may range, for example, 
In some embodiments of the present invention, the arrays between about 30 seconds and about 1 second in some 
may include between about 5 to 10 rows of microprojections 60 embodiments and between about 10 seconds and about 2 
by about 5 to 10 microprojections per row, or even between seconds in others. 
about 1 to 4 rows of microprojections by about 1 to 4 The foregoing and other objects, features and advantages 
microprojections per row. However, the exact arrangement of the invention will be apparent from the following more 
of the microprojections is not limiting. particular description of a preferred embodiment of the 
The present invention may further include a conductive 65 invention, as illustrated in the accompanying drawing 
mount for securing the micro projections in an arranged wherein like reference numbers represent like parts of the 
layout of the array. The conductive mount may be made in invention. 
SUMMARY OF THE INVENTION 
In one embodiment of the present invention, one or 
second comprising a second array Of electrically selected, for example, from a synthetic cationic copolymer, 
second reservoirs may be the Same or the gels may be 35 current. the pulse may be 
The microprojections may be made of any of the materials 50 
US 7,315,758 B2 
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BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. 1A-C are graphs showing an exponential decay 
pulse, a sign function current, and the pulse obtained when 
the sign function current is superimposed on the decay pulse 
in accordance with the present invention. 
FIG. 2 is a cross sectional view of microprojections 
inserted through the stratum corneum with microspheres 
containing a therapeutic agent being driven through the 
microconduits by electrokinetic transport forces in accor- 
dance with the present invention. 
FIGS. 3A-B are a cross sectional view and a perspective 
view of an array of microprojections. 
FIG. 4 is an exploded view of an exemplary device for the 
transdermal delivery of therapeutic agent in accordance with 
the present invention. 
DETAILED DESCRIPTION 
The present invention provides methods and devices for 
the transdermal delivery of therapeutic agents to a biological 
subject. Therapeutic agents suitable for transdermal delivery 
include, for example, medications, prescription drugs, non- 
prescription drugs, nutrients and metabolites. The agents 
that are suitable for transdermal delivery may be positively 
charged, negatively charged or they may be neutral and have 
no charge at all. Furthermore, the therapeutic agents may 
optionally be encapsulated by neutral or charged polymeric 
materials to provide a particle having a desired charge that 
may be the same as or different than the charge on the 
therapeutic agent itself for transdermal delivery to a bio- 
logical subject. Upon delivery into the biological subject, 
preferably the polymeric material degrades at a known rate, 
thereby releasing the therapeutic agent over a known period 
for a timed release of the agent. 
To provide transdermal delivery of a wide range of 
therapeutic agents to a biological subject, a driving force is 
required that drives the therapeutic agents through the skin. 
The greatest barrier to the transdermal delivery of therapeu- 
tic agents is the stratum corneum, the top layer of the 
epidermis of the skin. To overcome this barrier to the 
transdermal delivery of therapeutic agents through the stra- 
tum corneum, the present invention provides sharp micro- 
projections that cut micropassages through the stratum cor- 
neum. The present invention further utilizes electrokinetic 
transport techniques to drive the therapeutic agents along the 
microconduits and beyond the stratum corneum. Cutting 
micropassages through the stratum corneum reduces the 
electrical potential that must be applied across the skin when 
utilizing electrokinetic transport techniques. 
In one preferred embodiment, a patch containing the 
therapeutic agent is applied to the skin. The patch includes 
two arrays of microprojections that cut the microconduits 
through the stratum corneum and also function as the 
electrodes that are required by the electrokinetic transport 
techniques. In their function as electrodes, the surface of the 
microprojections must be electrically conductive. For the 
surface to be electrically conductive, the microprojections 
may be fashioned from electrically conductive materials or, 
alternatively, may be fashioned of a non-electrically con- 
ductive substrate that is coated or plated with an electrically 
conductive material. 
The microprojections of the present invention that are 
used to cut the stratum corneum do not penetrate the skin to 
the dermis layer, which is the layer of skin below the 
epidermis layer that contains the sensory nerve endings. 
Because the microprojections do not penetrate to the depth 
of the sensory nerve endings, the microprojections pain- 
lessly perforate the stratum corneum to provide microcon- 
duits in the skin through which the therapeutic agents may 
be driven by electrokinetic transport techniques. 
The microprojections may be made from materials that 
have sufficient strength and manufacturability to produce 
blades, such as, glasses, ceramics, rigid polymers, metals 
and metal alloys. Examples of metals and metal alloys 
include, but are not limited to, stainless steel, iron, steel, tin, 
10 zinc, copper, platinum, aluminum, germanium, nickel, zir- 
conium, titanium and titanium alloys consisting of nickel, 
molybdenum and chromium, metals plated with nickel, 
gold, rhodium, iridium, titanium, platinum, and the like. An 
example of glasses includes a devitrified glass such as 
15 “PHOTOCERAM’ available from Coming in Coming, N.Y. 
Examples of polymers include, but are not limited to, rigid 
polymers such as polystyrene, polymethylmethacrylate, 
polypropylene, polyethylene, “BAKELITE”, cellulose 
acetate, ethyl cellulose, styreneiacrylonitrile copolymers, 
20 styreneibutadiene copolymers, acrylonitrileibutadieneisty- 
rene (ABS) copolymers, polyvinyl chloride and acrylic acid 
polymers including polyacrylates and polymethacrylates. 
However, as noted above, if a non-electrically conductive 
material is used to form the microprojections, the micro- 
25 projection substrate must be plated or coated with an elec- 
trically conductive material. 
While the microprojections may be made of many differ- 
ent types of materials, preferred materials include tungsten, 
platinum, silicon, gold and silver. One preferred embodi- 
30 ment includes microprojections made of etched tungsten 
wire that is plated with platinum. Another preferred embodi- 
ment includes microprojections that are made of etched 
silicon plated with platinum, gold, silver or other noble 
metals. Methods of manufacturing arrays of microprojec- 
35 tions are well known to those having ordinary skill in the art. 
The microprojections preferably have a diameter of 
between about 0.5 pm and about 5 p at the tip. More 
preferably, the microprojections have a diameter of between 
about 1 pm and about 2 pm at the tip. In the proximal 
40 direction from the tip, the shafts of the microprojections are 
typically about 0.25 mm but may range between about 0.05 
mm and about 0.5 mm. 
Because the thickness of the human epidermis is between 
45 about 50 pm and about 150 p, the length of the micro- 
projections for human use preferably ranges between about 
50 pm and about 250 pm, more preferably between about 
150 pm and about 200 pm. However, since the device may 
be used on other animals as well, the microprojections are 
5o typically of sufficient length to penetrate the stratum cor- 
neum layer of the epidermis of a particular animal or group 
of animals, but preferably not so long as to penetrate into the 
dermis layer and make contact with the sensory nerve 
endings. 
The present invention includes cutting a plurality of 
microconduits through the stratum corneum by using arrays 
of the microprojections. Because the microconduits that are 
cut through the stratum corneum significantly decrease the 
current and potential required by the electrokinetic transport 
60 techniques, increasing the number of microconduits that are 
cut through the stratum corneum decreases the current and 
potential requirements of the electrokinetic techniques. 
The microprojections may have hooks on the tips. Hooks 
or barbs are often fashioned on the tips of the microprojec- 
65 tions to anchor them to the skin and are often preferred in 
order for the microprojections to remain in a skin-piercing 
relationship with the skin at all times. 
5 
55  
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The microprojections are arranged on an electrically 
conductive mount or base that secures the microprojections 
in the preferred layout of the array. The conductive mount 
may be formed as, for example, a conductive mounting rod 
or a conductive mounting plate. If the microprojections are 
fashioned from a block of silicon, then the silicon block 
forms the substrate of the conductive mounting block. Like 
the microprojections, the conductive mount must be elec- 
trically conductive since the conductive mounts form part of 
the electrodes that are required by the electrokinetic trans- 
port techniques. Therefore, the conductive mounts may be 
formed of materials that are electrically conductive or the 
conductive mounts may be formed of a non-electrically 
conductive substrate coated or plated with a conductive 
material. In one preferred embodiment, the conductive 
mount is made of non-conductive materials selected from 
polyvinylidene fluoride or polyethylene terephthalate as a 
nonconductive substrate, which is then plated with a noble 
metal to make the mount conductive. The mount may be 
made from any of the materials disclosed earlier as being 
suitable for making the microprojections. 
In one embodiment of the present invention, the electro- 
kinetic transport techniques that are used to drive the thera- 
peutic agents across the stratum corneum include electroos- 
mosis, iontophoresis, dielectrophoresis or combinations 
thereof. Iontophoresis involves the electrically induced 
transport of charged ions. Typically, relatively low transder- 
mal voltage of between about 0.1 V and about 5 V can be 
used to electrokinetically transport the therapeutic agents 
having either a negative or positive charge. Electroosmosis 
involves the movement of a solvent containing the thera- 
peutic agent through a membrane under the influence of an 
electric field. Dielectrophoresis involves the polarization 
and associated motion induced in particles by a non-uniform 
electric field. The phenomenon arises from the difference in 
the magnitude of the force experienced by the electrical 
charges within an unbalanced dipole, induced when a non- 
uniform electric field is applied. In a non-uniform field, the 
convergence of the field lines encourages uneven charge 
alignment and formation of an induced dipole moment. 
More simply, dielectrophoresis is defined as the lateral 
motion imparted on uncharged particles as a result of 
polarization induced by non-uniform electric fields. 
Therefore, non-uniform electrical fields must be gener- 
ated to induce transdermal delivery of the therapeutic agents 
through the microchannels when using dielectrophoresis as 
the driving force. A preferred embodiment of the present 
invention provides an electronic control module that 
includes a pulse generator to generate an exponential decay 
pulse between the two arrays of microprojections that are 
part of the two electrodes. An exponential decay pulse is 
preferred due to the long duration of voltage changes on 
decay, thereby creating the non-uniform electric field 
required for dielectrophoresis. Parameters to be considered 
in generating the pulse include the starting and ending 
voltage of the pulse, the number of pulses over a set period 
of time and the pulse resolution. These parameters may be 
varied for different applications of transdermal transport of 
therapeutic agents. 
In a preferred embodiment, the electrodes are powered by 
a power source that is one or more batteries although other 
8 
suitable power sources are acceptable. Preferably, the bat- 
teries provide between about 5 V and 10 V and more 
preferably, between about 7 V and 8 V. Capacity of the 
batteries are typically between about 1500 mAh and about 
3500 mAh, preferably between about 2300 mAh and about 
2500 mAh. An example of a suitable battery power supply 
is two photo DL123 lithium batteries. 
The DC current may be used in the present invention to 
i o  provide the electrokinetic transport techniques to drive the 
therapeutic agent through the stratum corneum. However, a 
preferred device includes a power inverter to convert the DC 
current, or even an AC current, to a desired AC current. 
When the AC current is superimposed on the exponential 
decay type pulse, the greatest non-uniform electrical field is 
generated to create the highest level of dielectrophoresis as 
the transdermal delivery driving force. FIGS. 1A-C are 
graphs showing an exponential decay pulse, a sign function 
20 current, and the pulse obtained when the sign function 
current is superimposed on the decay pulse. 
The electrokinetic transport of particles having a neutral 
charge occurs only by the slower technique of electroosmo- 
sis. Electrokinetic techniques are more efficient using ion- 
tophoresis and dielectrophoresis on charged particles. Par- 
ticles having a positive charge are successfully delivered 
transdermally from the anode electrode because positively 
charged particles are attracted by the cathode electrode. 
30 Likewise, particles having a negative charge are success- 
fully delivered transdermally from the cathode electrode 
because negatively charged particles are attracted by the 
anode electrode. 
To maximize the transdermal delivery of therapeutic 
agents, the charge of the particle to be transdermally deliv- 
ered may be controlled by encapsulating the therapeutic 
agent in a polymeric material having the desired charge. One 
advantage of such a method is that it facilitates the delivery 
40 of the therapeutic agent from both electrodes at once. For 
example, if the therapeutic agent naturally held a positive 
charge, the agent would have to be delivered only from the 
anode side of a device utilizing electrokinetic transport 
techniques. However, by encapsulating a portion of the 
45 therapeutic agent with a negatively charged polymeric mate- 
rial, the negatively charged microspheres can also deliver 
the therapeutic agent into the biological subject from the 
cathode side of the device, thereby increasing, perhaps even 
Methods for encapsulating therapeutic agents in poly- 
meric material are well known to those having ordinary skill 
in the art. Polymeric materials may be used that encapsulate 
neutral, negatively charged, or positively charged therapeu- 
tic agents in microcapsules having a positive, negative or 
neutral charge As is known to those having ordinary skill in 
the art, the microcapsules degrade harmlessly within the 
biological subject into which they were delivered, thereby 
60 releasing the therapeutic agent contained within the micro- 
capsules. In one preferred embodiment, the therapeutic 
agent is encapsulated in microspheres measuring approxi- 
mately 10 pm. Examples of suitable polymers that may be 
65 used for microencapsulation are shown in Table 1. 
EUDRAGIT is a registered trademark of Rohm&Hass, a 
German company. 
15 
25 
35 
5o doubling, the amount of agent that can be delivered. 
55 . 
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TABLE 1 
10 
Polymer 
Example Polymers for Encapsulation 
Source Crosslinking Agent Degradation Mechanism 
Collagen Cartilage glutaraldehyde NA 
Albumin Serum glutaraldehyde NA 
poly(Lactic acid) Synthetic none base hydrolysis 
poly(Lactide-co-glycolide) Synthetic none base hydrolysis 
poly(Hydroxy butyrate) Alcaligenes bacteria none enzymatic hydrolysis 
EUDRAGIT El00 (cationic copolymer) Synthetic none hydrolysis 
EUDRAGIT LlOO (anionic copolymer) Synthetic none hydrolysis 
In a preferred embodiment, the microspheres are sus- 
pended in a buffer gel, such as an agarose gel. The gel is held 
within a reservoir that surrounds the array of microprojec- 
tions. Therefore, when the microprojections cut through the 
stratum corneum, the microspheres that are suspended in the 
gel can flow through the gel under the electrokinetic driving 
force, through the microconduits cut by the microprojections 
and into the biological subject. 
FIG. 2 is a cross sectional view of microprojections 
inserted through the stratum corneum with microspheres 
containing a therapeutic agent being driven through the 
microconduits by electrokinetic transport forces in accor- 
dance with the present invention. Two arrays of micro- 
projections 11, 12 are used to cut microconduits 13 through 
the stratum corneum 14 layer of the epidermis 15. Each of 
the microprojections in the arrays 11,12 are held in place by 
a conductive mount 16, 17, respectively. It should be noted 
that the microprojections on the arrays 11, 12 do not extend 
to the dermis layer 18 of the skin that contains sensory nerve 
endings so there is no pain associated with piercing the 
stratum corneum 14 with the microprojections of the arrays 
11,12. The microprojections ofthe arrays 11,12 extend only 
into the lower layer of the epidermis 15, which is the stratum 
malphigii 21. 
Both the conductive mounts 16, 17 and the microprojec- 
tions in the arrays 11, 12 are electrically conductive, either 
because the parts are formed entirely of electrically conduc- 
tive material or because they are coated or plated with an 
electrically conductive material such as a noble metal. A 
power source, not shown, is connected to the conductive 
mounts 16, 17 and a circuit is completed between the two 
arrays 11,12 through the epidermal 15 and dermal 18 layers 
of the skin. Electric field lines 22 are formed through the 
skin layers 15, 18 to drive the positively charged micro- 
spheres 23 from the array 11 acting as the anode electrode 
to the array 12 acting as the cathode electrode. 
Each of the arrays 11, 12 of microprojections are con- 
tained within reservoirs 24 containing a buffer gel 25. The 
buffer gel 25 surrounds the microprojections of the arrays 
11, 12. As the electrical current is applied through the two 
arrays 11, 12, the microspheres 23 move through the gel to 
the microconduits 13 and into the skin layers 15, 18 where 
the therapeutic agent contained within the microspheres 23 
will be absorbed by the blood capillaries 26. 
FIGS. 3A-B are a cross sectional view and a perspective 
view of an array of silicon microprojections. Each of the 
silicon microprojections 11 are about 200 pm in length and 
the silicon substrate 31 of the microprojections 11 is coated 
with a conductive coating 32, typically a noble metal, such 
as palladium, platinum, gold or silver. For example, plating 
platinum on the silicon substrate 31 may be accomplished 
using 2000A platinum sputter coated on a 200A chromium 
stick layer as known to those having ordinary skill in the art. 
15 The microprojections 11 are etched from a block of 
silicon 33 before the base 33 and microprojections 11 are 
plated with the conductive coating 15. The array of micro- 
projections 11 is then mounted on a conductive mounting 
rod 34 that is in electrical communication with the power 
FIG. 4 is an exploded view of an exemplary device for the 
transdermal delivery of a therapeutic agent in accordance 
with the present invention, showing both front and back 
views. The therapeutic agent delivery device 50 includes a 
25 housing 51 having a display 52 for displaying information to 
the user and buttons 53 for querying the device 50 and for 
inputting information. 
The electronics board 54 provides the electronic controls 
module required to monitor and control the device 50. The 
30 electronics control module includes an electronic computer 
chip 55 that provides the control functions as well as data 
and information storage. A battery 56 provides the power 
source and other electronics 57 are included on the elec- 
tronics board such as a power inverter and pulse generator, 
35 neither shown. Also mounted on and protruding through the 
electronics board 54 are the arrays of microprojections 11. 
The reservoirs 58 contain the gel 61 in which the thera- 
peutic agent 62 is suspended. The therapeutic agent is 
typically encapsulated in a polymeric material. The micro- 
40 projections 11 protruding through the electronics board 54 
extend through the floor 63 of the reservoirs 58. The floor 63 
of the reservoirs 58 may be coated with an adhesive to hold 
the device 50 on the user. When placed on a user, the 
microprojections 11 extending through the floor 63 of the 
45 reservoirs 58 cut microconduits through the stratum cor- 
neum of the user. A disposable protective cover 64 protects 
the microprojections 11 from damage until the device 50 is 
ready for use. 
20 source, not shown. 
50 EXAMPLE 1 
Microprojections were prepared using the following 
method. A small glass vial, having a diameter of about 2.5 
cm, was filled with a solution used for electroetching wire 
55 into the microprojections. The vial was then closed with a 
plastic cap containing a septum. The solution used for 
electroetching depends upon the type of wire used for 
making the microprojections. For tungsten microprojec- 
tions, the solution used was 0.1 M NaOH. For platinum 
60 microprojections, the solution used was saturated NaN02 
solution. For gold microprojections, the solution used con- 
tained 10 g KCN and 5 g KOH per 40 mL of water. 
Three stainless steel needles were inserted through the 
septum so that the ends were about 5 mm above the solution 
65 level in the vial. A length of wire about 5 cm in length and 
having a thickness of about 0.25 mm, was inserted into the 
solution through the first needle to a depth of about 2 mm. 
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A second wire was inserted through the second needle and 
immersed in the solution shaped in a manner to form a spiral 
around the wire to be electroetched. When electroetching 
wire made of platinum or tungsten, the wire that was used 
to form a spiral around the wire to be electroetched was 
platinum, having a thickness of about 0.5 mm. When elec- 
troetching wire made of gold, the wire that was used to form 
a spiral around the wire to be electroetched was also gold, 
having a thickness of about 0.5 mm. The third stainless steel 
needle was used to vent the gas produced during the elec- 
troetching. 
AC potentials of 10 V, 17 V, and 20 V were applied for the 
W, Pt and Au microprojections respectively. AC current was 
monitored during the electroetching. The microprojections 
were ready when the AC current dropped to zero. The 
microprojections that were formed had very sharp tips 
having diameters of between about 1 and about 2 microme- 
ters. 
EXAMPLE 2 
A sample of pig’s skin taken from a pig’s foot was placed 
on a test cell sandwiched between the lower compartment 
and the top of the cell. The lower compartment of the cell 
was filled with 0.1 M phosphate buffer. A set of two arrays 
of conductive gold microprojections, each array having 
seven microprojections, was slowly moved towards the skin 
sample while measuring the resistance between the arrays. 
When the measured resistance dropped sharply from an 
open circuit reading to about 800 MQ, the microprojections 
were known to be in contact with the skin sample and the 
reading on the micrometer was recorded as the “zero” 
location from which a precise penetration depth could be 
measured. 
The arrays of microprojections were then raised above the 
skin sample and a suspension of microspheres in phosphate 
buffer was transferred into two compartments of the top 
portion of the cell. Typically, a 0.1 mL of suspension 
containing 10 mg of microspheres was used in each com- 
partment. The microprojections were then inserted into the 
skin sample to the desired depth of penetration from the 
“zero” location determined above. Exponential decay pulses 
were applied to the arrays. For some of the experiments, the 
microprojections were removed from the skin after skin 
perforation and then the skin sample was subjected to pulses. 
Parameters were varied during the experiments. The num- 
ber of pulses varied from between 0 and 400; pulse duration 
varied from between 0 and 20 seconds; pulse amplitude 
varied from between 3 and 80 V, and skin sample penetra- 
tion varied from between 100 p and 250 pm. 
After each experiment, the skin was removed from the 
cell, washed with DI water, and either placed in a vial 
containing 10% neutral-buffered formalin or frozen on dry 
ice. When ready for processing, the skin sample was 
washed, dehydrated using alcohol solutions up to 100% 
alcohol and embedded into parafin. The skin was then sliced 
into thin sections for microscopic examination. Microscopic 
examination revealed the passage of the therapeutic agent 
into the skin at depths greater than the depth of penetration 
by the microprojections. 
It will be understood from the foregoing description that 
various modifications and changes may be made in the 
preferred embodiment of the present invention without 
departing from its true spirit. It is intended that this descrip- 
tion is for purposes of illustration only and should not be 
12 
construed in a limiting sense. The scope of this invention 
should be limited only by the language of the following 
claims. 
What is claimed is: 
1. A device for transdermal delivery of a therapeutic agent 
a first electrode comprising a first array of electrically 
conductive microprojections for providing electrical 
communication through a skin portion of the subject to 
a second electrode comprising a second array of elec- 
trically conductive microprojections; 
a reservoir for holding the therapeutic agent surrounding 
the first electrode; 
a pulse generator for providing an exponential decay 
pulse between the first and second electrodes; and 
an electronic control module. 
2. The device of claim 1, further comprising a second 
reservoir for holding a second therapeutic agent surrounding 
the second electrode. 
3. The device of claim 2, wherein the second therapeutic 
agent is the same therapeutic agent surrounding the first 
electrode. 
4. The device of claim 2, further comprising a buffer gel 
contained in the reservoirs for suspending the therapeutic 
5. The device of claim 4, wherein the buffer gel is an 
agarose gel. 
6. The device of claim 4, wherein the buffer gel is selected 
from iontophoretic gels. 
7. The device of claim 2, wherein the buffer gel in the first 
reservoir is the same material as the buffer gel in the second 
reservoir. 
8. The device of claim 1, wherein the microprojections are 
adapted to provide perforation of the epidermis to a depth of 
9. The device of claim 1, wherein the microprojections are 
adapted to transiently perforate the epidermis to a depth 
greater than the thickness of a stratum corneum layer of the 
epidermis but less than a depth of sensory nerve ending 
locations. 
10. The device of claim 1, wherein the tip of the micro- 
projections have a diameter of between about 0.5 pm and 
about 5 p. 
11. The device of claim 1, wherein the tip of the micro- 
projections have a diameter of between about 1 pm and 
about 2 p. 
12. The device of claim 1, wherein the microprojections 
are made of materials selected from tungsten, platinum, 
13. The device of claim 1, wherein the microprojections 
are made of etched tungsten wire plated with platinum or 
gold. 
14. The device of claim 1, wherein the microprojections 
15. The device of claim 1, wherein the microprojections 
are made of silicon. 
16. The device of claim 15, wherein the microprojections 
are plated with platinum or gold. 
17. The device of claim 15, wherein the microprojections 
are plated with a metal. 
18. The device of claim 1, wherein each of the arrays 
measure between about 5 to 10 microprojections by about 5 
to 10 microprojections. 
19. The device of claim 1, wherein each of the arrays 
measure between about 1 to 4 microprojections by about 1 
to 4 microprojections. 
to a biological subject, comprising: 
lo 
l5 
2o 
25 agents. 
30 
35 between about 50 p and about 150 pm. 
40 
45 
5o silicon, gold or silver. 
55 are made of etched silicon block plated with platinum. 
60 
6 5  
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20. The device of claim 1, wherein each of the electrodes 
further comprise a conductive mount for securing the micro 
projections in an arranged layout of the array. 
21. The device of claim 20, wherein the conductive mount 
is a conductive mounting rod. 
22. The device of claim 20, wherein the conductive mount 
is a conductive mounting plate. 
23. The device of claim 20, wherein the conductive mount 
comprises a silicon substrate plated with a conductive coat- 
ing. 
24. The device of claim 20, wherein the conductive mount 
comprises a nonconductive substrate plated with a conduc- 
tive coating. 
25. The device of claim 24, wherein the nonconductive 
substrate is selected from polyvinylidene fluoride or poly- 15 
ethylene terephthalate. agent, comprising: 
26. The device of claim 24, wherein the conductive 
coating is a noble metal. 
27. The device of claim 1, further comprising a power 
source. 20 charged carriers: 
38. The device of claim 30, wherein the therapeutic agent 
is positively charged, the therapeutic agent is selectively 
microencapsulated within a polymer matrix that is nega- 
tively charged, positively charged, or has no charge. 
39. The device of claim 30, wherein the therapeutic agent 
has no charge, the therapeutic agent is selectively microen- 
capsulated within a polymer matrix that is negatively 
charged, positively charged, or has no charge. 
40. The device of claim 1, wherein the exponential decay 
i o  pulse is superimposed over a sign wave current. 
41. The device of claim 1, wherein the exponential decay 
pulse is superimposed over a constant current function to 
offset the constant current function to a net negative or a net 
positive current. 
42. A method for transdermal delivery of a therapeutic 
piercing a stratum corneum layer of skin with two arrays 
encapsulating the therapeutic agent into biocompatible 
5 
of conductive microprojections; 
28. The device of claim 27, wherein the power source is 
one or more batteries. 
29. The device of claim 28, further comprising a power 
inverter for transforming DC current from the one or more 
batteries to AC current to the electrodes. 
30. The device of claim 1, wherein the therapeutic agents 
are microencapsulated within a polymer matrix. 
31. The device of claim 30, wherein the polymer matrix 
is a synthetic cationic copolymer. 
32. The device of claim 30, wherein the polymer matrix 
u 
disposing the conductive microprojections into contact 
with the therapeutic agent; 
generating an exponential decay pulse between the two 
arrays of conductive microprojections to create a non- 
electrokinetically driving the therapeutic agent through 
43. The method of claim 42, wherein the exponential 
decay pulse is generated using parameters comprising a 
25 uniform electrical field; and 
the stratum corneum layer of skin. 
30 number of pulses, a voltage range, and a time period. 
is a synthetic anionic copolymer. 
33. The device of claim 30, wherein the polymer matrix 
is formed of materials selected from collagen or albumin. 
34. The device of claim 30, wherein the therapeutic agents 
are microencapsulated within micro spheres. 
35. The device of claim 34, wherein the microspheres are 
between about 5 microns and about 100 microns. 
36. The device of claim 34, wherein the microspheres 
have a diameter of between about 10 microns and about 70 
microns. 40 between about 30 seconds and about 1 second. 
37. The device of claim 30, wherein the therapeutic agent 
is negatively charged, the therapeutic agent is selectively 
microencapsulated within a polymer matrix that is nega- 
44. The method of claim 43, wherein the number of pulses 
45. The method of claim 43, wherein the voltage range is 
46. The method of claim 43, wherein the upper voltage of 
47. The method of claim 43, wherein the lower voltage of 
48. The method of claim 43, wherein the time period is 
49. The method of claim 43, wherein the time period is 
are between about 100 and 300 per minute. 
between about 60 V and about 3 V. 
the voltage range is between about 70 V and about 30 V. 
the voltage range is between about 20 V and about 0.5 V. 
35 
between about 10 seconds and about 2 seconds. 
tively charged, positively charged, or has no charge. * * * * *  
